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Abstract 
Background: Orthopaedic implant infections are treated by surgical debridement, systematic antibiotic treatment or 
local antibiotic treatment with antibiotic-loaded beads. Currently antibiotic concentrations in wound exudate, serum, 
urine or tissue samples are determined with HPLC or fluorescent spectrometric assays. Both methods are heavily influ-
enced due to proteins in the samples.
Questions/purposes: Is ELISA capable to detect gentamicin and vancomycin in protein-containing samples like 
serum and wound exudate.
Methods: Two specific competitive ELISA-assays were set-up to detect either gentamicin or vancomycin in protein-
rich samples. An antibiotic-BSA hapten was generated as a coatable antigen and commercially available antibodies 
were applied for downstream immunodetection.
Results: The developed ELISAs perform at a detection range of 2–500 ng/ml gentamycin and 20–5000 ng/ml vanco-
mycin. Both ELISAs were capable of detecting these antibiotics in human serum and wound exudate without being 
compromised by the presence of proteins. We did not detect cross-reactivity for gentamicin in the vancomycin ELISA 
or vice versa.
Conclusions: The antibiotic ELISAs detect gentamicin and vancomycin at low concentrations in protein-rich sam-
ples and they can be used as a high throughput and cost-effective alternative for chromatographic or fluorescent 
methods.
Clinical relevance: These ELISAs can be used to detect very low gentamicin or vancomycin concentrations in clinical 
samples or assess novel orthopaedic antibiotic release systems in in vitro and in vivo studies.
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Background
Orthopaedic infections are complex disorders, making 
prevention essential and treatment a challenging task 
(Calhoun et  al. 2009; Miclau et  al. 2010; Trampuz and 
Zimmerli 2006). Often the only possible treatment regi-
men to successfully treat a patient for orthopaedic infec-
tions is aggressive surgical debridement with intensive 
systemic antibiotic treatment, often supported by local 
antibiotic delivery (Calhoun et  al. 2009; Zimmerli 2006; 
Zimmerli and Ochsner 2003). Gentamicin and vanco-
mycin are two important antibiotics with a broad spec-
trum towards micro-organisms in severe orthopaedic 
infections (Fraimow 2009; Trampuz and Zimmerli 2006; 
Walenkamp et  al. 1998). Gentamicin is an aminoglyco-
side-antibiotic and is mostly used to treat gram-negative 
species and Staphylococci, while vancomycin is a glyco-
peptide-antibiotic and is used against specific antibi-
otic-resistant strains of Staphylococci (Fraimow 2009; 
Trampuz and Zimmerli 2006; Walenkamp et  al. 1998; 
Zimmerli 2006). These antibiotics are the most frequently 
used antibiotics admixed in polymethyl methacrylate 
(PMMA) bone cements for prosthesis fixation or as 
beads, both to serve as a local antibiotic delivery system 
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in the prevention or treatment of orthopaedic infections 
(Wahlig et al. 1978; Walenkamp 2001; Walenkamp et al. 
1998). Local antibiotic treatment is not only effective, but 
also avoids the toxicity of these antibiotics during sys-
temic treatment such as ototoxicity and nephrotoxicity 
(Contreiras et al. 2014; Han et al. 2014; Nagai and Takano 
2014; Ojano-Dirain et al. 2014; Walenkamp et al. 1986).
To follow the release of antibiotics from e.g. beads or 
spacers or determine systemic antibiotic concentrations 
in patient material (e.g. serum, urine, wound exudate 
and tissue samples), the quantification of the release of 
these antibiotics is essential (Wahlig et al. 1978). Initially 
these quantifications have been performed by fluores-
cent detection methods (Roche Diagnostics, approximate 
detection range 1–10 µg/ml) or chromatographic meth-
ods (e.g. high performance liquid chromatography 
(HPLC) with a minimal detection limit of 50  ng/ml) 
(Baietto et  al. 2010; Manyanga et  al. 2008; Wilson et  al. 
2003). In food and dairy applications gentamicin levels 
have been determined with enzyme-linked immunosorb-
ent assays (ELISA) with more sensitive detection limits 
(as low as 1 ng/ml) (Haasnoot et al. 1999; Jin et al. 2005a, 
b) and only recently an ELISA-based method to meas-
ure vancomycin was published, (Chianella et  al. 2013; 
Fujiwara et  al. 2012). However, the use of such ELISA-
based methods in human material has been minimally 
reported, possibly due to antibody restrictions and clini-
cal diagnostic product regulations.
The goal of this study was to develop an indirect com-
petitive ELISA-based detection method for gentamicin 
and vancomycin. In this setup a coated steady state 
antibiotic-hapten competes with the antibiotic in the 
sample for anti-antibiotic antibody binding. Due to this 
competition only antibodies bound to the steady state 
antibiotic-hapten will be detected by the conjugated sec-
ondary antibody, resulting in an HRP conjugate-depend-
ent colorimetric signal which is inversely correlated to 
the antibiotic concentration in the sample. Therefore a 
low concentration of antibiotic in the sample will result 
in a high colorimetric absorbance value in the assay and 
vice versa.
See the Additional file 1: Figure S1 for a schematic rep-
resentation of the ELISA setup.
To meet future requirements for (pre-) clinical use, 
our ELISA-based approach should be able to detect 
gentamicin and vancomycin in samples with a clinically 
relevant protein concentration and preferably in human 
serum and wound exudate as well.
Methods
Material collection, ethics and protein content
The used human serum originated from a single healthy 
volunteer. The collection of patient material (wound 
exudate) was approved by the Medical Ethics Commit-
tee of the Maastricht University Medical Centre (MEC 
approval number AZM/UM 11-4-023) and originated 
from a single patient.
Total protein concentration in human serum, human 
wound exudate (from hip revision surgery) and foetal 
calf serum (FCS, PAA Laboratories, Germany) was deter-
mined using the BCA method (Sigma-Aldrich, USA).
Hapten preparation
Gentamicin sulphate (Sigma-Aldrich, USA) and vancomy-
cin hydrochloride (Sigma-Aldrich, USA) were individually 
coupled to bovine serum albumin (BSA, PAA Laborato-
ries, Germany) using N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, Sigma-Aldrich, 
USA). The gentamicin-BSA hapten was prepared as fol-
lows: 50 mg BSA was dissolved in 1.5 ml phosphate buff-
ered saline (PBS, pH 7.4) which was subsequently added 
drop-wise to 24.5 mg gentamicin sulphate. Three hundred 
milligram EDC was dissolved in 1 ml demineralized water 
and added drop-wise to the gentamicin-BSA mixture 
under continuous agitation. After 1 h incubation at room 
temperature the mixture was stored over night at 4  °C. 
The procedure for the vancomycin-BSA hapten prepara-
tion was comparable with the gentamicin-BSA hapten, 
only with 70 mg BSA in 18 ml PBS added to 77.8 mg van-
comycin hydrochloride. The same amount of EDC was 
used only in 12  ml demineralized water. After 1  h incu-
bation at room temperature the mixture was stored over 
night at 4 °C.
The combination hapten of both gentamicin and vanco-
mycin with BSA was prepared using 33 mg BSA in 24 ml 
PBS added to 12  mg gentamicin sulphate and 36.7  mg 
vancomycin hydrochloride. Also 300 mg of EDC in 12 ml 
demineralized water was subsequently added drop-wise 
to the gentamicin-vancomycin-BSA mixture. After 1  h 
incubation at room temperature the mixture was stored 
over night at 4 °C.
After the 4  °C incubation step, uncoupled gentamicin 
and vancomycin as well as left-over EDC was removed 
from the preparation by dialysis (membrane cut-off value 
12–14  kDa, Sigma-Aldrich, USA) at 4  °C over a period 
of 3 days with daily refreshment of the dialysis solution 
[phosphate buffered saline (PBS), pH 7.4]. After dialysis 
the haptens were stored in aliquots at −80 °C.
Assessment of cross‑linking of antibiotic compounds 
to BSA in hapten preparations
Polypeptides in hapten preparations were separated by 
sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene 
fluoride (PVDF, GE Healthcare Life Sciences, USA) mem-
branes (for gentamicin-BSA, G-BSA) and nitrocellulose 
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membranes (Protran BA 83, GE Healthcare Life Sciences, 
USA) (for vancomycin-BSA, V-BSA) by electroblotting. 
Immuno-blotting was performed with the same antibod-
ies that are also used in the ELISA assay: mouse anti-gen-
tamicin monoclonal antibody (clone 26.16, Abcam, USA) 
and rabbit anti-vancomycin polyclonal antibody (AbD 
Serotec, UK). Secondary antibodies conjugated with 
horseradishperoxidase (HRP) (Dako, Denmark) were 
used to assess the bound primary antibody fraction to 
the antibiotic-BSA haptens on the membranes which is 
subsequently visualized by enhanced chemiluminescence 
(ECL).
Indirect competitive ELISA for gentamicin or vancomycin
The generated haptens were individually coated overnight 
at 4  °C to the surface of a 96-wells ELISA plate (10  ng 
coupled G-BSA, 1 µg V-BSA or 1.34 µg coupled G/V-BSA 
per well) in a 50  mM carbonate/bicarbonate buffer (pH 
9.6). After incubation the plate was washed 3 times with 
wash-buffer [PBS/Tween-20 (0.05  % v/v)]. Subsequently 
wells were blocked [1 h incubation with wash-buffer/BSA 
(5 % wt./v)] Calibration curve samples were prepared in 
PBS/BSA (5  % wt./v) (range gentamicin: 0–1000  ng/ml 
and vancomycin: 0–5000  ng/ml) also the test samples 
(clinical isolates or serum spiked with a known concen-
tration of antibiotics) were diluted 1000× in PBS/BSA 
before the initial measurement. Fifty microliter of the cal-
ibration curve sample or diluted test sample was pipet-
ted in each well of the ELISA plate. Fifty microliter of 
diluted primary antibody (mouse anti-gentamicin mon-
oclonal antibody (Abcam, USA), 7000× diluted in PBS/
BSA; rabbit anti-vancomycin polyclonal antibody (Abd 
Serotec, UK), 5000× diluted in PBS/BSA) was added to 
the samples and incubated for 1 h at room temperature 
(conditions and antibody dilutions were based on experi-
mental optimisation, data not shown). After incubation, 
the ELISA plate was washed 4 times with wash-buffer fol-
lowed by an additional blocking step with wash-buffer/
BSA (5 % wt./v) for 1 h. One-hundred microliter diluted 
secondary antibody (for gentamicin: rabbit anti mouse 
peroxidase (RAMPO, Dako, Denmark), 5000× diluted in 
PBS/BSA; for vancomycin: swine anti rabbit peroxidase 
(SWARPO, Dako, Denmark), 2000x diluted in PBS/BSA) 
was added to the wells and incubated for 1  h at room 
temperature after which the plate is washed 4 times with 
wash-buffer. After washing, 100  µl 3,3′,5,5′-tetrameth-
ylbenzidine (TMB, Sigma-Aldrich, USA) was added to 
each well to allow chromogenic detection of bound sec-
ondary antibodies. The reaction was stopped with 3  M 
sulphuric acid at the moment the absorbance of the nega-
tive control sample (0  ng/ml antibiotic) reached 0.5 at 
650  nm. After stopping the reaction, the absorbance at 
450 nm was measured using an ELISA reader (MultiSkan 
FC, Thermo Scientific). Due to the setup of the ELISA, 
the measured absorbance is inversely correlated with 
the antibiotic concentration present in the sample (for 
a detailed representation of the experimental procedure 
see Additional file 1: Figure S1). The antibiotic concentra-
tion present in the sample can be calculated based on the 
used calibration standards in a log–log scale.
Regression analysis
Calibration curve fitment was calculated in Micro-
soft Excel 2010 by the use of the VBA Analysis ToolPak 
(Microsoft, USA). Graphical representation of the data 
was performed in GraphPad Prism 5 (GraphPad, USA).
Results
Protein concentration
Total protein concentration measurements of human 
serum, wound exudate or FCS showed that these con-
tained 56, 46 and 37  mg total protein/ml, respectively. 
Based on these findings we decided to develop the ELISA 
assays in the presence of 50 mg/ml BSA to represent the 
protein concentration that generally occurs in the sam-
ples that we aim to measure.
Hapten evaluation
The development of these ELISAs required the coating 
of gentamicin or vancomycin to standard polystyrene 
ELISA wells. As the antibiotics themselves cannot be 
coated directly to well plates, we generated BSA haptens 
of each individual antibiotic by EDC-mediated coupling 
between a BSA carrier and the antibiotic. To acquire 
evidence of successful hapten generation we separated 
freshly prepared BSA-gentamicin and BSA-vancomycin 
haptens by SDS-PAGE, transferred the separated pro-
teins to nitrocellulose membranes and performed anti-
gentamicin or anti-vancomycin immunoblotting. To 
first visualize the total amount of SDS-PAGE-loaded 
hapten/protein, membranes were stained with Ponceau 
S after electro-blotting of SDS-PAGE gels. BSA runs at 
66 kDa in SDS-PAGE and besides a major 66 kDa band, 
we were able to confirm the presence of ~140 kDa (BSA 
dimer) and ~210 kDa (BSA trimer) main bands, as well 
as a smear of higher molecular weight BSA species which 
were generated as a result of the EDC cross-linking 
(Fig. 1a). A band running at the size for BSA was found in 
the BSA-vancomycin haptene preparation, but no other 
higher molecular weight BSA species were detected by 
Ponceau S staining (Fig.  1a). To confirm the coupling 
of each individual antibiotic to BSA, antibiotic-specific 
immunodetection was performed. As presented in 
Fig. 1b, immuno-blotting against gentamicin specifically 
generated a signal in the lane loaded with the BSA-gen-
tamicin hapten and not in the BSA-only lane. Similarly, a 
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specific signal was detected in the BSA-vancomycin lane 
as compared to the BSA-only lane after anti-vancomycin 
immuno-blotting. These data show that we were success-
ful in covalently coupling gentamicin or vancomycin to 
BSA for use as a hapten in the ELISA.
Optimal hapten amount for coating of the microtiter plate
To determine the optimal coating amount for the hap-
ten, three different hapten concentrations were coated 
on a microtiter plate. The gentamicin-BSA (G-BSA) 
hapten was coated at 1, 10 or 100  ng per well, while 
the vancomycin-BSA (V-BSA) hapten was coated at an 
amount of 0.1, 1 or 10  µg per well. Subsequently gen-
tamicin or vancomycin detection properties of these 
amounts were evaluated. Performing the ELISA with a 
gentamicin concentration series indicated an inversely 
correlated gentamicin concentration-dependant signal 
in all G-BSA hapten coated wells. The 10 ng/well G-BSA 
hapten coating showed the broadest interpretable rela-
tion between gentamicin concentration and the A450 
signal (Fig. 2a).
Performing the ELISA on the different hapten coat-
ing amounts with a vancomycin concentration series 
also indicated an inversely correlated vancomycin con-
centration-dependent signal in all V-BSA coated wells. 
Here, the 1  µg/well V-BSA hapten coating provided an 
optimal relation between the vancomycin concentration 
and the A450 signal. The 10 µg/well V-BSA haptene coat-
ing performed equally well and thus the 1 µg/well V-BSA 
became our condition of choice (Fig. 2b). From here on 
forward 10 ng/well G-BSA or 1 µg/well V-BSA were used 
to coat wells for any further experiments.
Specificity and sensitivity of the gentamicin 
and vancomycin ELISAs
The specificity of the gentamicin ELISA was assessed by 
performing the gentamicin ELISA using a concentration 
Fig. 1 Hapten evaluation. a Ponceau S staining indicates protein presence in the coupled haptens. b Immunoblotting indicates corresponding 
antibiotic presence in both coupled haptens specifically
Fig. 2 Coating optimization. a The optimal concentration of the 
gentamicin-BSA hapten was based on the pattern of the calibration 
curve, which indicated a concentration dependant absorbance. 
b The optimal concentration of the vancomycin-BSA hapten was 
determined on the relation between coating concentration and 
absorbance level
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series of either gentamicin or vancomycin. If the gen-
tamicin ELISA would be aspecific for distinguishing 
gentamicin from vancomycin, it is expected that with 
increasing vancomycin concentrations a vancomycin-
induced A450 shift would take place. The same principle 
was used for the vice versa situation where we deter-
mined the specificity of the vancomycin ELISA with 
a concentration series of gentamicin. The presence of 
vancomycin in the gentamicin ELISA did not result in a 
change of A450 absorbance in any of the tested concen-
trations, indicating that this ELISA setup is highly spe-
cific for gentamicin (Fig.  3a). These data also show that 
with this high specificity, the gentamicin ELISA is very 
sensitive and allows reliable detection of gentamicin in 
a range between 2 and 500  ng/ml. Gentamicin did not 
influence the vancomycin ELISA at any of the concen-
trations that were tested, indicating that also the van-
comycin ELISA set-up is very specific for vancomycin 
(Fig. 3b). The detection range of the vancomycin ELISA 
was determined to be reliable between 20 and 5000 ng/
ml vancomycin. To determine how the sensitivity of the 
ELISAs might depend on the antibiotic concentration 
in the sample, we used two separately prepared antibi-
otic concentration series. One series was used to gener-
ate a calibration curve and the other concentration series 
(“validation series” in the Figure) was subsequently meas-
ured and the antibiotic concentration in the series was 
estimated by using the calibration curve. This was done 
for both ELISAs separately. As shown in Fig.  3c, d we 
found that for both ELISAs the samples in the validation 
series generated absorbances that were within the 10  % 
deviation range of the measured absorbance of the cali-
bration curve (often used in commercial kits, to compen-
sate for potential pipetting errors, differences between 
wells and the standard deviation of the measurements) 
(Fig. 3c, d).
Antibiotic concentration in high‑protein samples
In an orthopaedic context, the gentamicin and vancomy-
cin ELISAs are expected to be used, amongst others, for 
determining antibiotic concentrations in clinical samples 
such as wound exudate from post-surgical drainage. To 
determine the performance of our ELISAs in this con-
text, human wound exudate (total protein concentration 
was 56.8 mg/ml, see above) was spiked with vancomycin 
to a final concentration of 50 µg/ml, to simulate a sample 
acquired from a patient undergoing antibiotic treatment. 
Before performing the ELISA, the sample was pre-diluted 
(1000×) in PBS/BSA. The vancomycin ELISA showed 
that the sample contained 53.5  µg/ml vancomycin, 
Fig. 3 Specificity and sensitivity of the antibiotic ELISAs. a The influence of vancomycin on the gentamicin ELISA. b The influence of gentamicin on 
the vancomycin ELISA. c The validation of the calibration curve of the gentamicin ELISA. Lines indicate upper and lower 10 % range of the calibra-
tion curve. d The validation of the calibration curve of the vancomycin ELISA. Lines indicate upper and lower 10 % range of the calibration curve. 
Error bars indicate standard deviation
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indicating a recovery of 107 %. The wound exudate was 
not spiked with gentamicin since the patient from whom 
the exudate was acquired was under gentamicin treat-
ment. However this offered us the opportunity to deter-
mine whether we could detect the presence of gentamicin 
in the patient’s wound exudate. Using our gentamicin 
ELISA we found that the wound exudate contained 5.0 µg 
gentamicin/ml. In addition we spiked human serum with 
gentamicin to a final concentration of 5  µg/ml to simu-
late a sample acquired from a patient undergoing antibi-
otic treatment. After initial sample dilution (1000×) the 
gentamicin ELISA determined that the serum sample 
contained 4.5 µg gentamicin/ml, indicating a recovery of 
90 %. Also, concentration series of gentamicin (Table 1) 
and vancomycin (Table 2) in PBS/BSA indicated recovery 
ranges between 91.6 and 108.8 %.
Multiple conjugates in one hapten
By using BSA as a coatable protein for generating the 
gentamicin and vancomycin haptens, we explored the 
possibility of combining different antibiotics in one hap-
ten coupling reaction. This potentially offers the oppor-
tunity to generate a combined assay for the detection of 
both antibiotics by using the same hapten in separate 
dedicated ELISAs. A combined hapten of both gen-
tamicin and vancomycin cross-linked to BSA indeed 
allowed the detection of either gentamicin or vancomy-
cin by their respective antibodies, in a comparable range 
as the individual ELISA protocols (Fig. 4). Furthermore, 
when this hapten was used for the ELISA detection of 
gentamicin, it was not influenced by vancomycin pres-
ence in the sample and vice versa.
Discussion
Orthopaedic infections are complex disorders often 
requiring surgical treatment and implantation of a local 
antibiotic delivery system. The use of antibiotic contain-
ing PMMA bone cement, beads or spacers is considered 
effective to prevent and treat such infections in combi-
nation with systemic antibiotics (Geurts 2011; Klemm 
1979; Wahlig 1972; Wahlig et al. 1978; Walenkamp et al. 
1998). Gentamicin beads and spacers generally remain 
implanted in the patient for a couple of weeks, before 
being surgically removed and substituted by a prosthesis 
or osteosynthesis materials (Geurts 2011; Walenkamp 
et al. 1998).
Currently HPLC and fluorescence-based methods are 
used to detect antibiotics in patient material (Baietto 
et  al. 2010; Manyanga et  al. 2008; Wilson et  al. 2003). 
These methods often require sample pre-treatments, are 
expensive, often insensitive or prone to be influenced 
by the high protein content in (patient) sample material 
(Baietto et  al. 2010; Manyanga et  al. 2008; Wilson et  al. 
2003). Currently, these methods are the method of choice 
to assess novel antibiotic release systems and coatings for 
clinical use. ELISA-based methods have been sparsely 
used for this purpose, possibly due to the lack of ready-
to-use protocols for ELISA-based antibiotic detection 
methods. ELISA-based methods are generally cheaper 
per sample, and better suited for high-throughput appli-
cations, compared to HPLC.
Table 1 Accuracy gentamicin ELISA
Gentamicin concentra‑












Human serum (5 ng/ml) 4.5 90.0
Table 2 Accuracy vancomycin ELISA
Vancomycin concentra‑












Hum. wound exudate  
(50 ng/ml)
53.5 107.0
Fig. 4 ELISA for gentamicin and vancomycin. A combined hapten 
of both gentamicin and vancomycin was used to coat wells for the 
detection of either gentamicin (black circles) or vancomycin (black 
squares) in a calibrations series of the respective antibiotics. Error bars 
indicate standard deviation
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Based on protocols derived from dairy and food-
industry applications we established ELISA-based 
assays to determine the concentration of gentamicin 
and vancomycin in patient material (serum and wound 
exudate). The gentamicin ELISA has a reliable detec-
tion range of 2-500  ng/ml with no detectable cross-
reactivity with vancomycin. The vancomycin ELISA 
is reliable between 20 and 5000  ng/ml without cross-
reactivity with gentamicin. Due to the graph character-
istics of the concentration-dependent calibration curve 
of gentamicin a linear regression can be used to esti-
mate the concentration in unknown samples. For van-
comycin a linear regression is not preferable due to the 
bending of the curve. Therefor a polynomial regression 
was used to estimate the vancomycin concentrations 
of unknown samples. The sensitivity of both ELISA’s is 
high, especially when compared to the detection lim-
its of the frequently used fluorescence-based detection 
systems and when compared to HPLC, where high-pro-
tein content is a notoriously hampering factor (Haas-
noot et al. 1999; Jin et al. 2005a, b; Wilson et al. 2003). 
The accuracy of the ELISA’s however will depend on the 
composition and complexity of the samples, therefore a 
possible optimization step may be required before spe-
cific application of the assay for quantitative measure-
ments. Still in this proof of concept we have shown that 
the ELISA’s are sensitive enough to allow accurate esti-
mation of the antibiotic concentrations in “unknown”/
spiked samples containing biologically common pro-
tein concentrations.
Recently novel experimental approaches to detect gen-
tamicin and vancomycin have been reported in literature 
(Chianella et  al. 2013; Fujiwara et  al. 2012). The group 
of Chianella recently described the use of a specific syn-
thetic coatable molecularly imprinted polymer nano-
particle (nanoMIP) for the detection of vancomycin in 
an ELISA-like way, instead of a conventional antibiotic-
protein hapten (Chianella et  al. 2013). Very low concen-
tration ranges (pM) are achieved by using the high-tech 
nanoMIP method. However, depending on the relevant 
concentrations to be measured, our low-tech ELISA setup 
provides an easy accessible and low-cost method for an 
in-house generated ELISA assay in the nM range. The 
group of Fujiwara described the use of a hapten consist-
ing of an antibiotic cross-linked to a protein like BSA. 
Only they choose a different cross-linking agent resulting 
in an antibiotic-cross-linker-BSA hapten (Fujiwara et  al. 
2012). In our approach we use a zero-length cross-linker 
(EDC) which results in an antibiotic-BSA hapten without 
the cross-linker in the hapten. A possible interaction of a 
cross-linker in the assay is thereby avoided.
Our data shows that the gentamicin ELISA requires 
a lower amount of hapten to be coated to the surface of 
the microtiter plate well as compared to the vancomy-
cin ELISA. This difference might be related to the size 
of the individual antibiotic compounds. Gentamicin is a 
relatively small molecule in comparison to vancomycin 
(about 1/3 in molecular weight). To achieve the coating 
of an equimolar amount of vancomycin as compared to 
gentamicin, it is imperative that more V-BSA hapten is 
coated to the well. However this does not fully explain 
the 100-fold larger coating dose required for the vanco-
mycin ELISA. In addition this could also be attributed 
by a difference in cross-linking efficiency during hapten 
formation, as seen in the immunoblotting results where 
the cross-linking of gentamicin resulted in BSA di-mers 
and tri-mers. Furthermore, the applied individual anti-
bodies for the detection of gentamicin and vancomycin 
are different and will differ in their antibody-antigen 
binding affinity. This difference in antibodies might thus 
influence the detection ranges in the assays and provide 
an explanation why we need to coat more V-BSA hapten 
to the well than G-BSA hapten. Although the gentamicin 
antibody does not detectably interact with vancomycin 
and the vancomycin antibody does not interact with gen-
tamicin, we cannot exclude that other antibiotics might 
cause aspecific interactions with the herein described 
antibodies, potentially resulting in incorrect calculations 
of the antibiotic concentration in the measured sample. 
Future application-specific evaluation of this potential 
bias should be performed, depending on the antibiotic.
Due to the nature of our ELISA setup, the protocol 
can be easily converted to establish ELISA tests for other 
antibiotics, provided the availability of antibodies and 
that such antibiotics possess carboxyl-groups or pri-
mary amines (like tobramycin, kanamycin, sisomicin and 
cefuroxime). This is due to the use of EDC as a cross-link-
ing agent to establish the antibiotic-BSA hapten. The ver-
satility of this ELISA setup also allowed the detection of 
both vancomycin and gentamicin by one hapten source, 
in which the two different antibiotics were combined. 
From an efficiency point-of-view this is particularly inter-
esting, since only one hapten has to be produced to allow 
detection of a variable set of antibiotics.
Conclusion
We here describe an easy-to-use protocol for the detec-
tion of gentamicin and vancomycin by ELISA. The pro-
tocol can be adapted relatively easy to other antibiotics, 
enabling the detection of antibiotics from experimental 
and clinical antibiotic release studies in several types of 
liquids, including high-protein samples.
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